News
Regeneron Pharmaceuticals is purchasing genetics and biotechnology company 23andMe and has vowed to protect customer data ...
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results